ArcticZymes Technologies ASA

Oslo Stock Exchange AZT.OL

ArcticZymes Technologies ASA EBITDA Margin for the year ending December 31, 2023: 26.61%

ArcticZymes Technologies ASA EBITDA Margin is 26.61% for the year ending December 31, 2023, a -23.84% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

ArcticZymes Technologies ASA EBITDA Margin for the year ending December 31, 2022 was 34.93%, a -28.98% change year over year.
ArcticZymes Technologies ASA EBITDA Margin for the year ending December 31, 2021 was 49.19%, a 5.85% change year over year.
ArcticZymes Technologies ASA EBITDA Margin for the year ending December 31, 2020 was 46.47%, a 1,070.81% change year over year.
ArcticZymes Technologies ASA EBITDA Margin for the year ending December 31, 2019 was 3.97%, a 125.65% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Oslo Stock Exchange: AZT.OL

ArcticZymes Technologies ASA

CEO	Mr. Michael Benjamin Akoh
IPO Date	Nov. 4, 2005
Location	Norway
Headquarters	Sykehusveien 23
Employees	53
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, In vitro diagnostics, and biomanufacturing. It offers salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; shrimp alkaline phosphatase and derived kits for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of double stranded DNA; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining DNA /RNA fragments. It operates in Norway, Germany, Lithuania, Italy, other countries in Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was incorporated in 1990 and is headquartered in Tromsø, Norway.

Key trends

Past 5 years